406 related articles for article (PubMed ID: 26311835)
1. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases.
Livermore DM; Mushtaq S; Warner M; Woodford N
J Antimicrob Chemother; 2015 Nov; 70(11):3032-41. PubMed ID: 26311835
[TBL] [Abstract][Full Text] [Related]
2. OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.
Morinaka A; Tsutsumi Y; Yamada M; Suzuki K; Watanabe T; Abe T; Furuuchi T; Inamura S; Sakamaki Y; Mitsuhashi N; Ida T; Livermore DM
J Antimicrob Chemother; 2015 Oct; 70(10):2779-86. PubMed ID: 26089439
[TBL] [Abstract][Full Text] [Related]
3. Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants.
Livermore DM; Warner M; Mushtaq S; Woodford N
Antimicrob Agents Chemother; 2016 Jan; 60(1):554-60. PubMed ID: 26552987
[TBL] [Abstract][Full Text] [Related]
4. Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae.
Mushtaq S; Vickers A; Woodford N; Haldimann A; Livermore DM
J Antimicrob Chemother; 2019 Apr; 74(4):953-960. PubMed ID: 30590470
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N
J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
7. In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae.
Morinaka A; Tsutsumi Y; Yamada K; Takayama Y; Sakakibara S; Takata T; Abe T; Furuuchi T; Inamura S; Sakamaki Y; Tsujii N; Ida T
Antimicrob Agents Chemother; 2016 May; 60(5):3001-6. PubMed ID: 26953205
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activities of the diazabicyclooctane OP0595 against AmpC-derepressed Pseudomonas aeruginosa.
Morinaka A; Tsutsumi Y; Yamada K; Takayama Y; Sakakibara S; Takata T; Abe T; Furuuchi T; Inamura S; Sakamaki Y; Tsujii N; Ida T
J Antibiot (Tokyo); 2017 Mar; 70(3):246-250. PubMed ID: 27999441
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Pharmacokinetics of the Combination of OP0595 and Cefepime in a Mouse Model of Pneumonia Caused by Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniae.
Kaku N; Kosai K; Takeda K; Uno N; Morinaga Y; Hasegawa H; Miyazaki T; Izumikawa K; Mukae H; Yanagihara K
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28507106
[TBL] [Abstract][Full Text] [Related]
11.
Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
[TBL] [Abstract][Full Text] [Related]
12. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
Mushtaq S; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
[TBL] [Abstract][Full Text] [Related]
13. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035
[TBL] [Abstract][Full Text] [Related]
14. Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.
Mushtaq S; Vickers A; Doumith M; Ellington MJ; Woodford N; Livermore DM
J Antimicrob Chemother; 2021 Jan; 76(1):160-170. PubMed ID: 33305800
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
[TBL] [Abstract][Full Text] [Related]
16. Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
Int J Antimicrob Agents; 2021 May; 57(5):106318. PubMed ID: 33716176
[TBL] [Abstract][Full Text] [Related]
17. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
19. Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.
Mushtaq S; Woodford N; Hope R; Adkin R; Livermore DM
J Antimicrob Chemother; 2013 Jul; 68(7):1601-8. PubMed ID: 23449829
[TBL] [Abstract][Full Text] [Related]
20. Structural Insights into the TLA-3 Extended-Spectrum β-Lactamase and Its Inhibition by Avibactam and OP0595.
Jin W; Wachino JI; Yamaguchi Y; Kimura K; Kumar A; Yamada M; Morinaka A; Sakamaki Y; Yonezawa M; Kurosaki H; Arakawa Y
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
